Advanced Bioaerosols Technology Core

先进的生物气溶胶技术核心

• 批准号: 10260848
• 负责人: Don L DeVoe
• 金额: $ 108.21万
• 依托单位: UNIV OF MARYLAND, COLLEGE PARK
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10260848
• 关键词: Address; Aerosols; Biocompatible Materials; Biological Assay; Biomedical Engineering; Cell Culture Techniques; Cell Line; Clinical; Clinical Research; Collection; Controlled Environment; Coupled; Development; Devices; Engineering; Environment; Evaluation; Exhalation; Exhibits; Ferrets; Fractionation; Gelatin; Goals; Growth; Heterogeneity; Human; Hydrogels; Individual; Influenza; Investigation; Liquid substance; Lung; Methods; Microfluidics; Modeling; Monitor; Mucins; Mucous body substance; Particle Size; Physical condensation; Population; Property; Research; Research Project Grants; Resolution; Respiratory System; Reverse Transcriptase Polymerase Chain Reaction; Risk; Risk Assessment; Route; Sampling; Solid; Source; Support System; Surface; System; Techniques; Technology; Variant; Viral; Virion; Virus; Water; ambient particle; base; density; design; digital; flu transmission; improved; influenzavirus; innovation; innovative technologies; instrument; model development; novel; pandemic disease; particle; prevent; respiratory; sample collection; tool; transmission process; virology

Project Summary/Abstract – Advanced Bioaerosol Technology Core The Advanced Bioaerosol Technology Core (ABTC) will develop a comprehensive suite of innovative technologies for improved sampling, fractionation, culture, and characterization of influenza virus aerosols to enable new analytical capabilities in support of the U19 research project goals. The advanced technologies developed through the ABTC will be employed within each individual research project to yield more effective studies of airborne transmission and infectivity through a combination of efficient ambient sampling to evaluate size-dependent distributions of infective virus within the clinical environment, and high-resolution individual exhaled breath sampling to elucidate the fundamental source terms needed for accurate transmission modeling. The ABTC team will leverage expertise across the fields of bioengineering, bioaerosol system engineering, and respiratory virology to develop 5 interconnected technologies for advanced bioaerosol analysis. In Aim 1, a set of compact instruments will be developed for the collection and parallel size-based fractionation of ambient environmental aerosols to enable distributed monitoring of airborne virus during the proposed clinical studies. In Aim 2, a second aerosol sampling instrument employing a unique exhaled breath sampling technology will be developed to provide high resolution aerosol fractionation and collection, allowing us to evaluate both viable and non-infective virus emission from individual donors across narrow particle size ranges. To enhance infectivity characterization for sampled virus particles, a synthetic mucus hydrogel will be advanced in Aim 3 as a novel sample target for the environmental sampler, providing improved virus capture and cell culture, greatly improving virus capture and viability for downstream infectivity assays. A digital cell culture array technology will be developed in Aim 4, enabling the direct isolation of individual aerosol particles captured by the exhaled breath sampler, and allowing us to evaluate distribution and clustering of both viable and non-infective virus units at single particle resolution. The ABTC team will also develop an optimized cell line that will be employed for the analysis of virus collected with the developed instruments to enhance evaluation of infectivity. The core will validate the developed technologies for aerosol sampling, capture, isolation, culture, and analysis through a set of ferret studies before integration with the proposed U19 research projects, and will execute the required assays using clinical samples to support the goals of RP1 and RP2. The results of the ABTC research efforts will yield the instruments and technologies needed to enhance our understanding of influenza aerobiology, from the determination of critical source terms to the evaluation of infective particle distributions within the environment, supporting significant improvements to influenza transmission modeling, risk analysis, and mitigation, while making important contributions toward advancing our understanding of other respiratory viral pandemic threats.

项目摘要/摘要 – 先进生物气溶胶技术核心 先进生物气溶胶技术核心（ABTC）将开发一套全面的创新技术 改进流感病毒气溶胶的采样、分级、培养和表征的技术 启用新的分析能力以支持 U19 研究项目目标。先进技术 通过 ABTC 开发的产品将应用于每个单独的研究项目，以产生更有效的结果 通过结合有效的环境采样来评估空气传播和传染性的研究 临床环境中感染性病毒的大小依赖性分布，以及高分辨率个体 呼气采样，以阐明准确传输建模所需的基本源项。 ABTC 团队将利用生物工程、生物气溶胶系统工程和 呼吸病毒学开发 5 种用于先进生物气溶胶分析的互连技术。在目标 1 中，一组 将开发紧凑型仪器，用于收集和并行基于尺寸的环境分馏 环境气溶胶，以便在拟议的临床研究期间能够对空气传播的病毒进行分布式监测。在 目标 2，第二台采用独特呼气采样技术的气溶胶采样仪将在 开发用于提供高分辨率气溶胶分离和收集，使我们能够评估可行的和 个体捐赠者在较窄的粒径范围内排放非感染性病毒。增强感染力 为了对病毒颗粒样本进行表征，合成粘液水凝胶将在 Aim 3 中作为一种新型 环境采样器的样品目标，提供改进的病毒捕获和细胞培养，大大提高 用于下游感染性测定的病毒捕获和活力。数字细胞培养阵列技术将 目标 4 中开发的，能够直接分离呼出气体捕获的单个气溶胶颗粒 采样器，使我们能够评估活病毒和非感染性病毒单位的分布和聚类 单粒子分辨率。 ABTC 团队还将开发一种优化的细胞系，用于 对使用开发的仪器收集的病毒进行分析，以加强对传染性的评估。核心将 通过一套方法验证已开发的气溶胶采样、捕获、分离、培养和分析技术 在与拟议的 U19 研究项目整合之前进行雪貂研究，并将执行所需的分析 使用临床样本来支持 RP1 和 RP2 的目标。 ABTC 研究工作的成果将产生 增强我们对流感空气生物学的理解所需的仪器和技术 确定评估环境内感染性颗粒分布的关键源项， 支持流感传播模型、风险分析和缓解的重大改进，同时 为增进我们对其他呼吸道病毒大流行威胁的了解做出了重要贡献。